+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Rufinamide"

Anticonvulsants Global Market Report 2024 - Product Thumbnail Image

Anticonvulsants Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
Epilepsy Forecast and Market Analysis to 2035 - Product Thumbnail Image

Epilepsy Forecast and Market Analysis to 2035

  • Drug Pipelines
  • July 2019
  • 345 Pages
  • Global
From
From
Antiepileptic Drugs Market - Forecast (2022 - 2027) - Product Thumbnail Image

Antiepileptic Drugs Market - Forecast (2022 - 2027)

  • Report
  • January 2022
  • 137 Pages
  • Global
From
The Treatment of Epilepsy. 3rd Edition - Product Thumbnail Image

The Treatment of Epilepsy. 3rd Edition

  • Book
  • July 2009
  • 1116 Pages
  • 9 Results (Page 1 of 1)
Loading Indicator

Rufinamide is a medication used to treat seizures associated with Lennox-Gastaut syndrome, a rare form of epilepsy. It is classified as an anticonvulsant and works by decreasing the number of abnormal electrical signals in the brain. Rufinamide is typically used in combination with other anticonvulsants to control seizures. It is available in tablet and oral suspension form. Rufinamide is a relatively new drug in the Central Nervous System (CNS) drugs market. It is used to treat a rare form of epilepsy, making it a niche drug. It is typically used in combination with other anticonvulsants, which can help to reduce the risk of side effects. Several companies are involved in the Rufinamide market, including Eisai, Inc., Sun Pharmaceutical Industries Ltd., and Mylan N.V. These companies manufacture and distribute the drug in various countries around the world. Show Less Read more